Previous close | 119.97 |
Open | 119.33 |
Bid | 148.10 |
Ask | 156.80 |
Strike | 850.00 |
Expiry date | 2024-06-21 |
Day's range | 119.33 - 119.97 |
Contract range | N/A |
Volume | |
Open interest | 11 |
Several stocks are breaking out and trading near all-time highs.
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi